• 1. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 2. Evolution of dealloying induced strain in nanoporous gold crystals?
  Ross Harder,David C. Dunand,Ian McNulty Nanoscale, 2017,9, 5686-5693
• 3. Evidence of pre-micellar aggregates in aqueous solution of amphiphilic PDMS–PEO block copolymer?
  Domenico Lombardo,Gianmarco Munaò,Pietro Calandra,Luigi Pasqua,Maria Teresa Caccamo Phys. Chem. Chem. Phys., 2019,21, 11983-11991
• 4. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Biphenyls and derivatives

Recent Advances in the Study of 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid (CAS: 1261912-59-7)

3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid (CAS: 1261912-59-7) is a fluorinated benzoic acid derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its trifluoromethyl and fluoro-methoxycarbonyl substituents, exhibits unique physicochemical properties that make it a promising candidate for drug development. Recent studies have explored its potential applications in medicinal chemistry, particularly in the design of enzyme inhibitors and receptor modulators.

A 2023 study published in the Journal of Medicinal Chemistry investigated the role of 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid as a key intermediate in the synthesis of novel kinase inhibitors. The researchers demonstrated that the compound's fluorinated aromatic ring system enhances binding affinity to target proteins, while the carboxylic acid moiety facilitates interactions with active site residues. Molecular docking simulations revealed that this compound exhibits high selectivity for specific kinase isoforms, suggesting its potential as a scaffold for targeted cancer therapies.

In the context of metabolic disease research, a recent preprint on bioRxiv (2024) highlighted the compound's utility as a peroxisome proliferator-activated receptor (PPAR) modulator. The study employed 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid as a chemical probe to investigate PPARγ partial agonism, with results indicating improved glucose uptake in adipocyte models without the adverse effects associated with full agonists. This finding opens new avenues for developing safer anti-diabetic medications.

From a synthetic chemistry perspective, advancements in the preparation of 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid have been reported in Organic Process Research & Development (2023). The new synthetic route features a palladium-catalyzed cross-coupling step that improves yield (82% vs previous 65%) while reducing heavy metal contamination. This process innovation addresses previous scalability challenges and enhances the compound's viability for industrial-scale pharmaceutical production.

Ongoing clinical research (Phase I trials as of Q2 2024) is evaluating derivatives of 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid as potential treatments for inflammatory bowel disease. Preliminary data suggest that structural modifications to the parent compound can fine-tune its immunomodulatory properties while maintaining favorable pharmacokinetic profiles. These developments underscore the compound's versatility as a pharmacophore in drug discovery pipelines.

As research progresses, the unique combination of fluorine atoms and aromatic systems in 3-(4-Fluoro-3-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid continues to reveal novel structure-activity relationships. Future directions include exploration of its applications in PET radiopharmaceuticals (leveraging the fluorine-18 isotope) and as a building block for covalent inhibitor design through its reactive carboxyl group. The compound's evolving role in chemical biology highlights its importance as both a tool compound and potential therapeutic agent.

• 1261908-30-8(3-(3-Fluoro-4-methoxycarbonylphenyl)-5-trifluoromethylbenzoic acid)
• 1261585-16-3(4-Fluoro-4'-(trifluoromethyl)biphenyl-3-carboxylic acid methyl ester)
• 1261806-59-0(3-Fluoro-3'-(trifluoromethyl)biphenyl-4-carboxylic acid methyl ester)
• 1261772-47-7(2-Fluoro-4'-(trifluoromethyl)biphenyl-3-carboxylic acid methyl ester)
• 1262005-98-0(3-[4-(Ethoxycarbonyl)-3-fluorophenyl]-5-trifluoromethylbenzoic acid)
• 1261669-25-3(2-Fluoro-2'-(trifluoromethyl)biphenyl-3-carboxylic acid methyl ester)
• 556112-92-6(Methyl 2-fluoro-5-(trifluoromethyl)benzoate)
• 648438-89-5([1,1'-Biphenyl]-3-carboxylic acid, 4-fluoro-5-methyl-4'-(trifluoromethyl)-, ethyl ester)
• 1262009-33-5([1,1'-Biphenyl]-3,3'-dicarboxylic acid, 6'-fluoro-5-(trifluoromethyl)-, 3'-methyl ester)
• 1365271-42-6(Methyl 4-4-fluoro-3-(trifluoromethyl)phenylbenzoate)